CYTOSORBENTS CORP (CTSO)
US23283X2062 - Common Stock
CytoSorbents Rights Offering Begins
To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco....
CytoSorbents Announces Rights Offering
Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate
CytoSorbents Announces Rights Offering
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024...
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions...
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor...
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in...
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in...
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CytoSorbents (NASDAQ:CTSO) just reported results for the second quarter of 2024...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this...
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires...
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents to Report Q2 2024 Financial and Operating Results...
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents regains compliance with Nasdaq minimum bid price requirement ...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
CytoSorbents new modern website launch unifies corporate and product websites and highlights
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
CytoSorbents CEO Dr. Phillip Chan to highlight its innovative critical care and cardiac surgery blood purification therapy at AAPI Conference this weekend...
CytoSorbents Secures $20 Million Credit Facility
Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR in the U.S. and Canada
CytoSorbents Secures $20 Million Credit Facility
$20 million credit facility provides CytoSorbents with important non-dilutive capital to support its regulatory and commercialization objectives...
CytoSorbents 公司宣布 CytoSorb® 獲得台灣監管部門批准
當地是全球最先進的醫療保健系統之一，現在引進這個迄今應用於 75 個國家近 25 萬次治療的強大的血液淨化技術，用於治療危疾和心臟手術患者...
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
Brings a powerful blood purification technology used to treat critically ill and cardiac surgery patients in nearly a quarter million treatments across 75 countries to date to one of the most progressive healthcare systems in the world
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
Taiwan FDA approval of CytoSorb brings powerful blood purification therapy to critically ill and cardiac surgery patients in the country...